{"denoms":[{"counts":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"71"},{"groupId":"BG002","value":"104"}],"units":"Participants"}],"groups":[{"description":"Patients received vismodegib 150 mg orally once daily until disease progression; intolerable toxicity, most probably attributable to vismodegib; or withdrawal from the study.","id":"BG000","title":"Metastatic Basal-Cell Carcinoma"},{"description":"Patients received vismodegib 150 mg orally once daily until disease progression; intolerable toxicity, most probably attributable to vismodegib; or withdrawal from the study.","id":"BG001","title":"Locally Advanced Basal-Cell Carcinoma"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.4","value":"61.6"},{"groupId":"BG001","spread":"16.8","value":"61.2"},{"groupId":"BG002","spread":"15.2","value":"61.4"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"41"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"63"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}]}